Coral AI

Overview

Coral AI is a document intelligence and workflow automation platform — not a voice AI company. This is the critical distinction that separates it from Infinitus, SuperDial, and Prosper AI. Coral does not make phone calls to payers. Instead, it uses AI agents, computer vision, OCR, and NLP to automate document-heavy front-office workflows: reading inbound referral packets and faxes, extracting structured data, verifying eligibility, evaluating clinical criteria against payer requirements, and preparing prior authorization requests — all operating as an overlay on providers’ existing systems (Forbes).

The phrase “within existing systems” reflects a deliberate architectural choice. CEO Ajay Shrihari explains: “Legacy vendors attempted to reconstruct everything from scratch. We work alongside the tools that providers already utilize, delivering value from day one” (Forbes). Coral’s AI agents read documents in whatever format they arrive (PDFs, handwritten forms, insurance card images), extract structured data, and surface it through Coral’s interface while flowing data back into existing systems. Human staff review and submit the prepared documents — Coral operates as a human-in-the-loop system, not fully autonomous end-to-end.

Coral positions itself as a next-generation replacement for legacy RPA (UiPath, Automation Anywhere) in healthcare — using AI that understands documents contextually rather than clicking through predictable screen states (Lightspeed blog).

Competitive Positioning

Coral AI occupies a different product category from the voice AI PA companies. It automates the document processing and PA preparation that happens before and around payer phone calls, while Infinitus and SuperDial automate the phone calls themselves. The two categories are potentially complementary: a provider might use Coral to prepare and package PA requests and use Infinitus to follow up on their status by phone.

Coral competes more directly with legacy RPA vendors (UiPath, Automation Anywhere), clearinghouse platforms (Waystar, Availity), and payer-side PA automation (Cohere Health). Its overlay approach — no rip-and-replace required — is well-suited for the fragmented provider market. However, Coral is the earliest-stage company in this batch by a wide margin ($2M seed vs. $102.9M for Infinitus, $162M for Tennr), with limited enterprise readiness indicators.

Recent Developments (2024-2026)

• 2024: Founded; team spent months embedded with clinic staff before writing code
• Early 2025: $2M seed round led by Lightspeed India Partners (Rohil Bagga, Dev Khare); strategic angels from OpenAI, Zapier (ex-Director of AI Andrew Berman), and Rotech Healthcare (PR Newswire)
• March-October 2025: Revenue grew 8x in 7 months; reached 500K patient workflows per month
• October 2025: Public launch / out-of-stealth; Forbes feature; Ashish Singh (Senior Partner, Bain & Company, founder of Bain’s healthcare practice) joined as strategic advisor (Forbes)
• Late 2025-2026: Hiring aggressively; expanding into health systems, payers, and DME suppliers as prospective accounts

Client Types

Coral targets healthcare providers — specifically DME suppliers (DASCO Home Medical Equipment is the primary named customer), infusion centers, specialty pharmacies, and radiology practices (trycoral.ai). There is no explicit pharma manufacturer, PBM, or health plan customer presence as of April 2026. The mention of specialty pharmacies as a target vertical creates a logical path into pharma-adjacent services, but this remains unproven.

Technology Platform

Coral’s stack includes custom-trained computer vision/OCR for healthcare documents (handling handwriting, flipped images, unclear text), NLP/document understanding for structured data extraction, LLMs for agentic workflows, rules-based policy logic for payer criteria evaluation, and next-gen browser automation for payer portal interaction (Lightspeed blog). The company maintains a documented internal accuracy bar of 99%+ before shipping any workflow module; publicly stated operating accuracy is 98.7% with an 85% PA obtainment rate. Specific EHR integrations are not publicly disclosed, and no SOC 2 or HIPAA certification claims were found in public materials — a potential enterprise procurement barrier.

Financial Context

Metric	Value
Total funding	$2M (seed)
Revenue	Multi-million dollar ARR in <6 months of selling
Revenue growth	8x in 7 months
Employees	~10-30 (estimated)
Revenue stage	Early revenue, rapid growth
Key investors	Lightspeed India Partners, angels from OpenAI, Zapier
Workflows processed	500K+ per month

Analyst Observations

Defensibility: Emerging. Coral’s defensibility depends on building a proprietary training dataset of healthcare documents (similar to Tennr’s RaeLM approach but far earlier). The “within existing systems” overlay approach is smart for provider adoption but does not create strong switching costs. At $2M seed, the company is undercapitalized relative to the enterprise healthcare sales cycle.

Commoditization risk: High. Document processing and portal automation for PA are increasingly commoditized capabilities — major EHR vendors, clearinghouses, and better-funded startups (Tennr has $162M and 100M+ training documents) can build similar solutions. Coral’s path to defensibility requires rapidly accumulating proprietary healthcare document data and building domain-specific AI that outperforms general-purpose tools.

Acquisition target potential: Moderate. At this stage, Coral is more likely to be acqui-hired or acquired for its team and early traction by a larger healthcare IT vendor, EHR platform, or RCM company. Its document AI capabilities would complement Infinitus’s or SuperDial’s voice AI, creating a full-stack PA automation solution.

Key risk: Coral competes in the same general space as Tennr (document AI for healthcare intake/PA), but Tennr has 80x more funding, 100M+ training documents vs. Coral’s undisclosed count, and established enterprise relationships. Coral must either find a differentiated niche (specialty pharmacy overlay, payer portal automation) or demonstrate dramatically better unit economics to justify its position against Tennr’s scale advantage.

Therapeutic Focus

broad/all

Target Customers

Healthcare providers (clinics, DME/home medical equipment providers, specialty healthcare centers, infusion centers, specialty pharmacies, radiology practices)

Sources

• PR Newswire, Forbes, TryCoral.ai, LinkedIn Company, Lightspeed blog